People · Operator
Named in public records as an officer, director or promoter · active 2008–2015 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Milestone Pharmaceuticals Inc. | — | Pharmaceuticals | Series C | $91.3M | $2.8B | 2015 |
| Eiger Biopharmaceuticals Inc | — | Biotechnology | Series A | $70.9M | $216.9M | 2008 |
| Trius Therapeutics Inc | — | Biotechnology | Series B | $49.3M | $1.2B | 2009 |
Paul Truex at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul Truex on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Nina Kjellson | 1 | 11 |
| Risa Stack | 1 | 9 |
| Brian G. Atwood | 1 | 8 |
| David Kabakoff | 1 | 7 |
| John Finn | 1 | 5 |
| John Schmid | 1 | 4 |
| Theodore R. Schroeder | 1 | 4 |
| Scott Weiner | 1 | 4 |
| Nina S. Kjellson | 1 | 4 |
| Jeffrey Stein | 1 | 4 |
| Glen Sato | 1 | 4 |
| Eric Linsley | 1 | 4 |
| Thomas Dietz | 1 | 4 |
| Wenjin Yang | 1 | 2 |
| Nina G. Kjellson | 1 | 2 |
| Paul F. Truex | 1 | 2 |
| Risa P Stack | 1 | 2 |
| Jeffrey Glenn | 1 | 2 |
| Keith Vendola | 1 | 2 |
| David S. Kabakoff | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.